Difference between revisions of "Team:Valencia UPV/Collaborations"

Line 200: Line 200:
 
padding-top: 15px;
 
padding-top: 15px;
 
margin-top: 0px;">
 
margin-top: 0px;">
<p></p> </div><div class="col-md-9"><h3>Ecuador</h3><h4>Team Project</h4><p>Ecuador iGEM team has been working on the development of a new biomaterial to speed up the healing in bone injures. This biomaterial called (C-lastine), is based on the cross-linking of bacterial cellulose and Elastin-like polypeptides. This cross-linking is mediated by a carbohydrate binding domain and a BMP2 protein (an osteoblasts differentiation inducer). To achieve this objective they are using E.Coli as a biofactory, specifically C41 strain which is resistant to Cellulose synthase operon protein D, codified by gene bcsD and responsible of pore formation in the membrane allowing cellulose to exit the cell. The final result is a bandage matrix that can be applied to the wound during a surgical intervention.</p><h4>Collaboration</h4><p> If we think about it, Printeria is a kind of biofactory so, we thought that trying to make Ecuador’s biomaterial in Printeria would be a good trial to show that Printeria is ready to become something greater in the biotechnological industry and why not, it could be used in hospitals as well. However, due to the fact that there were problems with the size of the parts for Golden Gate and with the customs, it could not become a reality. This idea would be developed with Imperial College. Instead, we did several things.</p>
+
<p></p> </div><div class="col-md-9"><h3>Ecuador</h3><h4>Team Project</h4><p><a href="https://2018.igem.org/Team:Ecuador">Ecuador iGEM team</a>has been working on the development of a new biomaterial to speed up the healing in bone injures. This biomaterial called (C-lastine), is based on the cross-linking of bacterial cellulose and Elastin-like polypeptides. This cross-linking is mediated by a carbohydrate binding domain and a BMP2 protein (an osteoblasts differentiation inducer). To achieve this objective they are using E.Coli as a biofactory, specifically C41 strain which is resistant to Cellulose synthase operon protein D, codified by gene bcsD and responsible of pore formation in the membrane allowing cellulose to exit the cell. The final result is a bandage matrix that can be applied to the wound during a surgical intervention.</p><h4>Collaboration</h4><p> If we think about it, Printeria is a kind of biofactory so, we thought that trying to make Ecuador’s biomaterial in Printeria would be a good trial to show that Printeria is ready to become something greater in the biotechnological industry and why not, it could be used in hospitals as well. However, due to the fact that there were problems with the size of the parts for Golden Gate and with the customs, it could not become a reality. This idea would be developed with Imperial College. Instead, we did several things.</p>
  
 
<p>We did a survey to get some feedback from the potential users of both projects. It consisted in a video and then a survey to fill out.</p>
 
<p>We did a survey to get some feedback from the potential users of both projects. It consisted in a video and then a survey to fill out.</p>

Revision as of 10:11, 18 September 2018

Stack Multipurpose HTML Template